Definition · Plain-language
EU Clinical Trials Regulation
The EU Clinical Trials Regulation — Regulation (EU) No 536/2014 — harmonises the rules for authorising and overseeing clinical trials of medicines across the European Union through a single submission portal and database.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What the Regulation does
Regulation (EU) No 536/2014 establishes a harmonised framework for the conduct of clinical trials on medicinal products for human use across the European Union and European Economic Area. It replaces the older Clinical Trials Directive (2001/20/EC), whose national-by-national implementation had led to divergent procedures between member states. The Regulation introduces a single application submitted through one portal, a coordinated assessment involving the member states concerned, and harmonised rules on authorisation, conduct, safety reporting and transparency, aiming to make multinational trials more consistent and efficient while maintaining participant protection.
The Clinical Trials Information System (CTIS)
Central to the Regulation is the Clinical Trials Information System (CTIS), the single entry point through which sponsors apply for and manage clinical-trial authorisations in the EU and EEA. CTIS comprises a secure workspace for sponsors and regulators and a public website that makes information about trials available, supporting the Regulation’s transparency objectives. By channelling applications and decisions through one system, CTIS underpins the coordinated assessment model and gives regulators and the public a common reference for trials conducted across multiple member states.
Transition and timeline
The Regulation entered into application in January 2022, when CTIS went live, beginning a phased transition from the Directive. New trial applications could use CTIS from that point, and after a transition period its use became mandatory for all new clinical-trial applications, with the changeover completed in 2023 and remaining trials migrating to the new framework. This staged approach allowed sponsors and authorities to adapt while moving towards a single, harmonised system. The Regulation governs the regulatory process for trials; it does not itself address clinical or treatment decisions.
Key facts
At a glance
- Definition: EU regulation harmonising clinical-trial authorisation and oversight.
- Legal instrument: Regulation (EU) No 536/2014.
- Replaces: Clinical Trials Directive 2001/20/EC.
- Key system: Clinical Trials Information System (CTIS).
- Application: Entered into application January 2022 (CTIS go-live).
- Mandatory use: CTIS became mandatory for new trials, completed in 2023.
Common misconceptions
What people often get wrong
Often heard: The EU Clinical Trials Regulation is just an updated name for the old Clinical Trials Directive.
Actually: It is a different legal instrument. As a Regulation it applies directly and uniformly across member states, replacing the Directive’s nationally implemented approach with a single portal and coordinated assessment.
Often heard: CTIS is optional for sponsors running EU trials.
Actually: After the transition period, use of CTIS became mandatory for new clinical-trial applications, with the changeover completed in 2023.
Often heard: The Regulation sets out how patients should be treated in a trial.
Actually: It governs the regulatory process — authorisation, oversight, safety reporting and transparency — not clinical or treatment decisions, which remain matters of medical practice and trial design.
Going deeper
